{"id":"alemtuzumab-s-c","safety":{"commonSideEffects":[{"rate":"null","effect":"Infections"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Neutropenia"}]},"_chembl":{"chemblId":"CHEMBL1201587","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Alemtuzumab is a monoclonal antibody that targets the CD52 antigen on the surface of lymphocytes, leading to their depletion and immunosuppression.","oneSentence":"CD52-targeting monoclonal antibody","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:33:28.770Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia"}]},"trialDetails":[{"nctId":"NCT02689453","phase":"PHASE1","title":"Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-19","conditions":"T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL), Peripheral T-Cell Lymphoma (PTCL)","enrollment":11},{"nctId":"NCT00951457","phase":"PHASE1, PHASE2","title":"Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2009-03","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":20},{"nctId":"NCT01186640","phase":"PHASE2","title":"Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2010-06","conditions":"T-cell-prolymphocytic Leukemia","enrollment":16},{"nctId":"NCT01392079","phase":"PHASE2","title":"Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2008-02","conditions":"Chronic Lymphocytic Leukemia","enrollment":135},{"nctId":"NCT00634881","phase":"PHASE1, PHASE2","title":"Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2003-11","conditions":"Chronic Lymphocytic Leukemia","enrollment":13},{"nctId":"NCT00147901","phase":"PHASE2","title":"Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2005-01","conditions":"B-cell Chronic Lymphocytic Leukemia","enrollment":61},{"nctId":"NCT00725231","phase":"PHASE3","title":"Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP","status":"UNKNOWN","sponsor":"University of Göttingen","startDate":"2008-02","conditions":"Peripheral T Cell Lymphoma, Unspecified, Angioimmunoblastic Lymphadenopathy, Extranodal NK/T-cell Lymphoma","enrollment":274}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Alemtuzumab s.c.","genericName":"Alemtuzumab s.c.","companyName":"German CLL Study Group","companyId":"german-cll-study-group","modality":"Biologic","firstApprovalDate":"","aiSummary":"CD52-targeting monoclonal antibody Used for Chronic lymphocytic leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}